Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant vs Letrozole in ER+ HER2- breast cancer
NCT04191382Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised trial of amcenestrant in breast cancer (3 arms), sponsored by Sanofi. Primary endpoint: Percent Change From Baseline in Ki67 Level at Day 15. Started Feb 2020; status: terminated.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04191382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191382.